Delipidated retroviruses as potential autologous therapeutic vaccines--a pilot experiment.
This pilot experiment in a simian immunodeficiency virus (SIV) chronic infection model aimed at extending our previous findings that vaccination with delipidated SIV resulted in more potent and diversified antiviral responses (1). Macaques chronically infected with SIVmac239 treated with antiretroviral therapy (ART) were vaccinated with autologous delipidated virus via consecutive lymph node targeted immunizations-1, 1 and 10 mug of virus spaced monthly. Results showed all animals had lasting viral load reduction approaching 1 log compared to set-point, and disease delay. Delipidation may enhance processing/ presentation of viral antigen eliciting potent antiviral control even at such late infection stage.
Kitabwalla
Moiz
M
Lipid Sciences, Inc., 7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566, USA. mkitabwalla@lipidsciences.com
Ansari
Aftab A
AA
Villinger
Francois
F
Akeefe
Hassibullah
H
Conner
Adam P
AP
Mayne
Ann E
AE
Hildreth
James E K
JE
D000818:Animals; D000906:Antibodies / Q000737:chemistry; D000956:Antigens, Viral / Q000737:chemistry; D000998:Antiviral Agents / Q000494:pharmacology; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008253:Macaca mulatta; D010865:Pilot Projects; D012190:Retroviridae / Q000378:metabolism*; D018449:SAIDS Vaccines / Q000737:chemistry*; D013997:Time Factors
D000906:Antibodies; D000956:Antigens, Viral; D000998:Antiviral Agents; D018449:SAIDS Vaccines; D007371:Interferon-gamma